IP Verse

Binding Molecules For Bcma And Cd3 - EP2780374B1

PatentPatent Analysis

EP2780374

AMGEN
Application Number
EP12803509A
Filing Date
Nov 15, 2012
Status
Revoked
Aug 25, 2023
Grant Date
Aug 21, 2019
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP3661562B1
EP3570885B1
EP4209499B1

Bibliography

The patent EP2780374B1 was granted to Amgen on Aug 21, 2019 following the initial filing on Nov 15, 2012 under the application number EP12803509A . The current legal status of the patent is Revoked.

AI Generated Summary New

Patent Family

Patent Family

Patent Oppositions (7)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

KONIG SZYNKA TILMANN VON RENESSEMay 22, 2020ADMISSIBLE
JAMES POOLEMay 21, 2020ADMISSIBLE
MATHYS & SQUIREMay 21, 2020ADMISSIBLE
REGENERON PHARMACEUTICALSMay 21, 2020ADMISSIBLE
SANOFIMay 20, 2020ADMISSIBLE
PFIZERMay 4, 2020ADMISSIBLE
JANSSEN BIOTECHApr 14, 2020ADMISSIBLE

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents